authors
- Shirakawa, Kotaro
- Schröder, Sebastian
- Ott, Melanie
- Marmorstein, Ronen
- Meier, Jordan
- Nimer, Stephen
- Verdin, Eric
- Wang, Lan
- Man, Na
- Maksimoska, Jasna
- Sorum, Alexander W
- Lim, Hyung W
- Lee, Intelly S
- Shimazu, Tadahiro
- John Newman, MD, PhD
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
- Overview
- Research
- Identity
- View All
Overview
publication date
- January 1, 2016
published in
- eLife Journal
has subject area
- Acetyl Coenzyme A
- Acetylation
- Animals
- Antineoplastic Agents
- Binding, Competitive
- Catalytic Domain
- Cell Line, Tumor
- Core Binding Factor Alpha 2 Subunit
- Diflunisal
- Enzyme Inhibitors
- Gene Expression Regulation, Leukemic
- HEK293 Cells
- Humans
- Leukemia, Myeloid, Acute
- Leukocytes
- Mice
- Mice, SCID
- Oncogene Proteins, Fusion
- Protein Binding
- RUNX1 Translocation Partner 1 Protein
- Salicylic Acid
- Signal Transduction
- Structure-Activity Relationship
- Xenograft Model Antitumor Assays
- p300-CBP Transcription Factors